AOD-9604 Dose Adjustments for Black / African Ancestry Patients

What AOD-9604 Is and How It Works

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176 to 191) of human growth hormone, with an added tyrosine residue at its N-terminus. Its primary mechanism involves stimulating lipolysis and inhibiting lipogenesis without activating the full growth hormone receptor signaling cascade. This distinction matters. The peptide does not raise IGF-1, does not promote insulin resistance in the way exogenous GH can, and does not appear to stimulate longitudinal bone growth [1].

Mechanism of Action

Heffernan et al. Demonstrated in 2001 that the hGH fragment 176-191 stimulated lipolysis in both rodent and human adipose tissue and improved fat oxidation in obese mice without the diabetogenic effects seen with full-length growth hormone 1. The peptide acts through a mechanism that is distinct from the GH receptor pathway, though the exact receptor target has not been fully characterized.

Regulatory Status

AOD-9604 is not approved by the FDA for any indication. It received a Generally Recognized as Safe (GRAS) determination from the FDA in 2014, but only for use as a food substance, not as an injectable therapeutic 2. In clinical practice, it is obtained through compounding pharmacies and prescribed off-label. The World Anti-Doping Agency prohibited it in 2023 under the category of growth hormone releasing factors. These regulatory gaps are relevant to every patient, but they carry particular weight for populations already subject to health-system disparities.

Why Ethnicity-Specific Data Is Missing for AOD-9604

The short answer: AOD-9604 never completed a large Phase III trial. The existing human data comes from a limited number of studies, most conducted in Australia with predominantly White cohorts. No published trial has reported ethnicity-stratified subgroup analyses for this peptide 1.

The Clinical Trial Gap

A 2004 Phase IIb trial (Metabolic Pharmaceuticals Ltd) enrolled 300 obese adults and tested AOD-9604 orally at doses of 1 mg, 5 mg, 10 mg, and 25 mg daily for 12 weeks. The trial did not meet its primary weight-loss endpoint. Demographic breakdowns by race or ethnicity were not published in the public results. That trial remains the largest human dataset for AOD-9604, and its failure to reach Phase III means no large, diverse, multi-center study was ever conducted 3.

What This Means for Black Patients

Without ethnicity-stratified pharmacokinetic (PK) or pharmacodynamic (PD) data, clinicians cannot make evidence-based race-specific dose adjustments. Any dosing modification must be driven by individual patient factors: body composition, renal clearance, comorbidities, and treatment response. This is not unique to AOD-9604. Many compounded peptides lack diversity data because they were never required to generate it through the standard approval pipeline.

Growth Hormone Axis Differences by Ancestry

While direct AOD-9604 data across ethnic groups does not exist, the broader literature on growth hormone physiology offers context. The GH/IGF-1 axis shows measurable variation by ancestry, and those differences could theoretically influence response to GH-derived peptides.

IGF-1 and GH Secretion Patterns

A cross-sectional analysis from NHANES III found that Black adults had lower mean serum IGF-1 levels compared with White adults after adjusting for age, sex, and BMI 4. Separate studies have shown that Black adolescents exhibit higher peak GH secretion amplitude but similar 24-hour integrated GH concentrations compared with White adolescents 5.

These differences in GH-axis physiology have not been tested for clinical relevance to AOD-9604. The peptide's mechanism bypasses the classical GH receptor, so baseline IGF-1 levels may not predict response. Still, prescribers should be aware that reference ranges for GH-axis biomarkers vary by ancestry when interpreting monitoring labs.

Body Composition Considerations

Black adults, on average, carry higher lean mass and lower visceral adipose tissue relative to total fat mass compared with White adults at the same BMI, according to data from the Pennington Biomedical Research Center 6. Because AOD-9604 targets adipose tissue lipolysis, differences in fat distribution could influence where and how quickly the peptide exerts its effects. A patient with predominantly subcutaneous fat distribution may respond differently than one with high visceral adiposity, regardless of race.

Comorbidity-Driven Dose Considerations

Race-based dosing is a blunt instrument. Comorbidity-based dosing is precise. For Black and African ancestry patients considering AOD-9604, three overlapping clinical factors deserve attention.

Renal Function and CKD Risk

Black Americans have 1.5 to 3 times the prevalence of chronic kidney disease compared with White Americans, driven in part by higher rates of hypertension and diabetes 7. The 2021 CKD-EPI creatinine equation, which removed the race coefficient, is now the standard for eGFR estimation 8.

AOD-9604 is a small peptide (molecular weight approximately 1,800 Da) likely cleared renally. No formal renal impairment PK study exists for AOD-9604. In the absence of data, standard peptide pharmacology principles apply: patients with eGFR <45 mL/min/1.73 m² may accumulate peptide fragments, and dose reduction or extended dosing intervals should be considered. Monitor eGFR at baseline and every 3 months in patients with known CKD or hypertensive nephropathy.

Hypertension and Cardiovascular Context

Hypertension affects approximately 56% of Black adults in the United States, compared with 48% in White adults, per the American Heart Association's 2024 statistical update 9. AOD-9604 itself has not demonstrated cardiovascular effects in published human studies, but the metabolic context matters. Patients using AOD-9604 for weight management are often on concurrent antihypertensive therapy.

Black patients on ACE inhibitors or ARBs show differential blood pressure response patterns compared with other populations, a well-documented pharmacogenomic finding linked to lower circulating renin levels and differences in the RAAS pathway 10. While AOD-9604 does not interact with the RAAS, prescribers managing these patients should track blood pressure closely during peptide-mediated weight loss, as even modest fat loss (3 to 5% of body weight) can alter antihypertensive medication requirements.

G6PD Deficiency Screening

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects 10 to 14% of males of African descent 11. AOD-9604 has no known oxidative stress mechanism and is not expected to trigger hemolytic episodes in G6PD-deficient patients. No case reports of AOD-9604-related hemolysis exist. Screening for G6PD before starting AOD-9604 is not required based on current evidence. If a patient is already known to be G6PD-deficient, standard monitoring suffices.

Pharmacogenomics and AOD-9604

No pharmacogenomic annotations exist for AOD-9604 in PharmGKB, CPIC, or DPWG databases as of May 2026. This is not surprising. Pharmacogenomic guidance requires well-powered studies linking genetic variants to drug metabolism, efficacy, or toxicity, and those studies were never conducted for AOD-9604.

Relevant Genetic Variation in African Ancestry Populations

African ancestry populations carry the greatest genetic diversity of any global group, with more polymorphic sites per genome on average 12. This diversity affects drug-metabolizing enzymes. CYP2D6, for example, has allele frequencies that differ substantially between African and European populations, with higher rates of gene duplication (ultrarapid metabolizer phenotype) in some East African populations 13.

AOD-9604, as a peptide, is not metabolized by cytochrome P450 enzymes. Peptides are generally degraded by peptidases and proteases rather than hepatic CYP pathways. This means CYP polymorphisms are unlikely to affect AOD-9604 clearance. The clinical relevance of protease polymorphisms (such as dipeptidyl peptidase variants) to AOD-9604 metabolism has not been studied.

What Pharmacogenomic Testing Can and Cannot Tell You

A pharmacogenomic panel will not provide AOD-9604-specific guidance. It can, however, inform concurrent medication management. For Black patients on metformin, statins, or antihypertensives alongside AOD-9604, pharmacogenomic testing for OCT1/OCT2 transporter variants (relevant to metformin) or SLCO1B1 (relevant to statins) may reduce adverse event risk from the broader medication regimen 14.

Practical Dosing Protocol

Given the absence of ethnicity-specific guidance, the following protocol applies standard peptide dosing principles with individualized adjustments based on clinical factors common in Black and African ancestry patients.

Starting Dose

Begin at 250 mcg subcutaneously once daily, injected into abdominal subcutaneous tissue, 30 minutes before breakfast. This applies regardless of ancestry. The injection site should rotate within the periumbilical area to reduce lipodystrophy risk.

Titration

After 2 weeks at 250 mcg, if tolerated and no adverse effects are noted, increase to 300 mcg daily. Maximum dose in clinical use is typically 500 mcg daily, though no dose-ranging study has established an optimal ceiling. The 2004 Phase IIb trial used oral doses up to 25 mg, which are not directly comparable to subcutaneous injection due to bioavailability differences 3.

Dose Modifications for Specific Scenarios

For patients with eGFR 30 to 44 mL/min/1.73 m²: start at 250 mcg every other day and monitor renal biomarkers at 2-week intervals. For patients with eGFR <30: AOD-9604 use is not recommended until renal PK data becomes available.

For patients with BMI above 40: no dose increase beyond 500 mcg daily is supported by evidence. Higher doses do not equate to faster lipolysis in the absence of pharmacodynamic data justifying escalation.

Monitoring Schedule

Baseline labs should include: fasting glucose, HbA1c, comprehensive metabolic panel (including eGFR by 2021 CKD-EPI), lipid panel, and blood pressure. Follow-up labs at 4 weeks, 12 weeks, and every 12 weeks thereafter. Blood pressure should be checked at every visit, especially in patients on concurrent antihypertensives.

The Problem with Race-Based Dosing

The broader medical community has moved away from race-based dose adjustments. The removal of the race coefficient from the eGFR equation in 2021 reflected a recognition that race is a social construct and a poor proxy for the biological variables (such as muscle mass or creatinine generation) it was intended to capture 8.

Individual Variation Exceeds Group Averages

Within-group genetic and metabolic variation among Black Americans is larger than the between-group variation that separates Black and White population averages 12. A 65-year-old Black woman with stage 3 CKD and a BMI of 32 has a fundamentally different risk profile than a 28-year-old Black man with normal renal function and a BMI of 38, even though both fall under "Black / African ancestry." Dosing should reflect the individual, not the demographic.

When Ancestry Information Is Clinically Useful

Ancestry data becomes clinically relevant when it points to specific, actionable genetic risks. Sickle cell trait screening, G6PD deficiency awareness, and APOL1-associated nephropathy risk are examples where African ancestry flags a specific variant worth testing. For AOD-9604, no such ancestry-linked variant has been identified. Until one is, ancestry should inform vigilance around comorbidities (especially CKD and hypertension), not peptide dose selection.

What Black Patients Should Ask Their Prescriber

Patients of African ancestry considering AOD-9604 should ask five direct questions before starting therapy. First: has your provider verified the compounding pharmacy sources pure AOD-9604 with certificate of analysis? Second: what is your baseline eGFR, and was it calculated using the 2021 CKD-EPI equation without a race modifier? Third: are you on any antihypertensive medications that may need dose adjustment as weight changes? Fourth: is your provider monitoring fasting glucose, given that GH-derived peptides can theoretically affect glucose homeostasis even if AOD-9604 data suggests minimal impact? Fifth: what is the stopping protocol if no measurable body composition change occurs at 12 weeks?

These questions are not race-specific. They are good clinical practice that becomes especially important in a population carrying a higher baseline burden of metabolic and renal disease.